Inicio
Explorar
nav.journalClub
Tendencias
Más
Synapse
⌘+K
Synapse
Idioma
Español
Español
Table 3 from Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer | Synapse
September 16, 2025
Ver artículo completo
Table 3 from Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer
RY
Rona Yaeger
Memorial Sloan Kettering Cancer Center
JM
Jean-François Martini
Pfizer (United States)
LP
Lincoln W. Pasquina
Boston Foundation
Ver todo
Puntos clave
Concordance analysis reveals the detection accuracy of FoundationOne Liquid CDx for BRAF V600E in colorectal cancer.
High concordance rates indicate it is a viable option for BRAF V600E testing in clinical settings.
The methodology used allows for an effective comparison against traditional testing methods.
Findings support the integration of FoundationOne Liquid CDx in routine colorectal cancer diagnostics.
Resumen
Concordance analysis results
Preguntar a la IA
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Ver artículo completo
Preguntar a la IA
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Ver artículo completo
Cite This Study
Copy
Yaeger et al. (Tue,) studied this question.
synapsesocial.com/papers/68d4565b31b076d99fa5b181
https://doi.org/https://doi.org/10.1158/2767-9764.30083895